Skip to main content
Premium Trial:

Request an Annual Quote

Tata Consultancy Pens Protein Optimization Deal With Italian Biotech

NEW YORK, Aug. 4 (GenomeWeb News) - Tata Consultancy Services will provide its optimization tools to biotech start-up Congenia, the company said today.

 

Congenia, which is "promoted" by Italy's Genextra group, will use the technology to study P66, a target protein that Congenia believes is involved in several age-related diseases. The drug maker intends to develop optimized drug leads based on the protein.


TCS will use modules of its own product, TCS Bio-Suite, to work on the target protein. It will screen a "virtual fragment library" of tens of thousands of potential lead molecules to "predict which molecules might bind themselves to the target protein, thereby inhibiting its function," the company said.

 

TCS said it will also produce a "first-cut analysis" of the ADMET profile of the lead molecules.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.